Important considerations regarding the widespread use of doxycycline chemoprophylaxis against sexually transmitted infections

J Antimicrob Chemother. 2023 Jul 5;78(7):1561-1568. doi: 10.1093/jac/dkad129.

Abstract

Rates of sexually transmitted infections (STIs) continue to rise across the world and interventions are essential to reduce their incidence. Past and recent studies have indicated this may be achieved using doxycycline post-exposure prophylaxis (PEP) and this has sparked considerable interest in its use. However, many unanswered questions remain as to its long-term effects and particularly potentially negative impact on human microbiomes and antimicrobial resistance among STIs, other pathogens, and commensals. In this review, we discuss seven areas of concern pertaining to the widespread use of doxycycline PEP.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chemoprevention
  • Doxycycline / therapeutic use
  • HIV Infections* / drug therapy
  • Humans
  • Incidence
  • Post-Exposure Prophylaxis
  • Sexually Transmitted Diseases* / drug therapy
  • Sexually Transmitted Diseases* / epidemiology
  • Sexually Transmitted Diseases* / prevention & control

Substances

  • Doxycycline